IP Group – capital markets day summary
Greg Smith, IP Group’s CEO, discussed how the company is positioned to exploit the significant value potential in UK science and technology. He also explained the UK scale-up funding opportunity. Anne Dobrée, Investment Director at Parkwalk (IP Group’s EIS fund management business), introduced the company as UK’s most active investor in university spinouts. Finally, Mark Reilly, Managing Partner at IP Group, discussed scientific innovation as the next big driver and how IP Group is identifying companies offering breakthrough innovation across life sciences, deeptech and cleantech.
Hysata
Hysata is developing a breakthrough hydrogen electrolyser and accelerating the global transition to net zero. The company remains on course to demonstrate a 100kW hydrogen system this year, which will be an important validation point that its technology is commercially scalable (it is pursuing gigawatt-scale manufacturing). The company’s technology exhibits a 95% system efficiency versus 75% for the incumbent solutions. Hysata is addressing the green hydrogen market, which is projected to be worth £17bn (representing 200m tonnes) by 2030 across zero-carbon production of steel, fertilisers and methanol, which together make up c 12% of global carbon emissions and where there are no practical alternatives to green hydrogen. The company completed an oversubscribed US$111m Series B round in May 2024.
Intrinsic
Intrinsic are commercialising a cutting-edge non-volatile memory developed at University College London which is based on CMOS compatible resistive random-access memory (RRAM), a solution which can read data 10x to 100x quicker, and write it 1,000x faster, as well as being much smaller, than existing in-market options. IP Group believes that this silicon-based RRAM will transform the semiconductor industry, bringing fast and efficient memory to embedded systems and offering exciting new opportunities in hardware for AI.
Genomics
Genomics developed a unique rapid genetic screening platform that enables a prevention-first approach to healthcare by using its risk prediction tools to ensure more people are on the right screening, diagnosis and treatment pathways. The company uses large-scale genetic information to develop precision healthcare tools and bring new understanding to drug discovery.
